Skip to main content
Veterinary Medicines

Salmosan Vet, 500 mg/g powder for suspension for fish treatment

Authorised
  • Azamethiphos

Product identification

Medicine name:
Salmosan Vet, 500 mg/g powder for suspension for fish treatment
Salmosan Vet 500 mg/g pulver til behandlingssuspensjon til fisk.
Active substance:
  • Azamethiphos
Target species:
  • Atlantic salmon
Route of administration:
  • Water-borne use

Product details

Active substance and strength:
  • Azamethiphos
    500.00
    milligram(s)
    /
    1.00
    gram(s)
Pharmaceutical form:
  • Powder for suspension for fish treatment
Withdrawal period by route of administration:
  • Water-borne use
    • Atlantic salmon
      • Fish meat
        10
        degree day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP53AF17
Authorisation status:
  • Valid
Authorised in:
  • Norway
Available in:
  • Norway
Package description:
  • Heat-sealed PVA water soluble bag containing 20 g or 100 g of product contained in a sealed polyethylene lined paper sachet. 5 x 20g or 2 x 100 g packages in a box
  • Heat-sealed PVA water soluble bag containing 20 g or 100 g of product contained in a sealed polyethylene lined paper sachet. 2 x 100 g packages in a box.

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Benchmark Animal Health Norway AS
Marketing authorisation date:
Manufacturing sites for batch release:
  • Freja Transport & Logistics A/S
Responsible authority:
  • Norwegian Medicines Agency
Authorisation number:
  • 13-9892
Date of authorisation status change:
Reference member state:
  • Norway
Procedure number:
  • NO/V/0011/001
Concerned member states:
  • United Kingdom (Northern Ireland)
Generic of:

Documents

Summary of Product Characteristics

English (PDF)
Published on: 14/01/2022
Download
Norwegian (PDF)
Published on: 24/11/2022

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Norwegian (PDF)
Published on: 2/11/2023
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."